Takeda to Slash 4,500 Jobs Amid Restructuring, Biogen Reports Mixed Tau-Targeting Alzheimer's Data
Takeda Pharmaceutical announced plans to eliminate approximately 4,500 positions in fiscal year 2026, marking one of the largest workforce reductions in recent pharmaceutical history. The cuts are part of a broader restructuring aimed at centralizing corporate functions and reducing costs following the company's $62 billion Shire acquisition in 2019.
Meanwhile, Biogen released mixed results from a mid-stage clinical trial for diranersen, an experimental Alzheimer's treatment targeting tau protein. While the drug reduced tau levels in spinal fluid and brain tissue, the correlation to cognitive decline slowing was modest.
Job Cuts and Cost Savings
Takeda expects the restructuring to generate annual savings exceeding $1.27 billion by fiscal 2028. The company did not specify which roles or regions will be affected, nor the timeline for the reductions.
The overhaul comes as Takeda prepares for several high-profile product launches, including a narcolepsy treatment, a blood disorder drug, and a psoriasis medicine. Higher selling, general and administrative costs related to these launches will be partially offset by the restructuring program.
“This is a necessary step to streamline operations and focus on our core therapeutic areas,” a Takeda spokesperson said in a statement. “We are committed to supporting affected employees through this transition.”
Biogen's Tau-Directed Approach
Biogen's diranersen is an antisense oligonucleotide designed to reduce production of tau protein, which forms toxic tangles in Alzheimer's patients' brains. In the Phase 2 study, the drug lowered tau levels in both cerebrospinal fluid and brain imaging, and those reductions were linked to a slowing of cognitive decline.
However, the results were described as mixed because the cognitive benefit did not meet statistical significance across all endpoints. Multiple previous attempts to slow Alzheimer's by targeting tau have failed, making any positive signal noteworthy.
“Reducing tau is a key goal, but proving it translates into meaningful cognitive benefits has been elusive,” said Dr. Maria Torres, a neurologist at the University of California, San Francisco, who was not involved in the trial. “These data provide cautious optimism but are far from conclusive.”
Diranersen must be administered via spinal injection, a significant drawback compared to antibody treatments that can be infused intravenously. Biogen plans to advance the drug into late-stage trials.
Background
Takeda's restructuring follows years of debt accumulation and operational complexity from the Shire acquisition. The company has been selling non-core assets and focusing on high-growth areas in rare diseases, neuroscience, and oncology.
Biogen's tau-targeting effort is part of a broader shift beyond amyloid-beta, the protein targeted by its controversial Alzheimer's drug Aduhelm. Tau accumulation correlates more closely with cognitive decline than amyloid does, making it a compelling but challenging target.
What This Means
The Takeda layoffs signal continued consolidation in the pharmaceutical industry as companies prioritize profitability over scale. The job cuts could affect research and development centers, particularly in regions with overlapping functions from the Shire merger.
For Alzheimer's treatment, Biogen's mixed data underscore the difficulty of modifying the disease's trajectory. If diranersen succeeds in later trials, it could open a new class of therapies targeting tau, but the spinal injection method may limit patient adoption. Investors will watch for more detailed data presentations at upcoming medical conferences.
Together, these developments highlight the high-stakes environment in drug development and corporate restructuring, where billions in savings and potential blockbuster drugs hang in the balance.